Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2025-06-23 00:00:00 ET · period of report 2025-06-18 · accession 0000912282-25-000697 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-23 | 2025-06-18 | QNCX | Hannah Brendan | COO, CCO, CBO | A - Grant | $1.20 | +37.7K | 334.3K | +13% | +$45.3K |
| D | 2025-06-23 | 2025-06-18 | QNCX | Hannah Brendan | COO, CCO, CBO | A - Grant | $0.13 | +37.7K | 37.7K | New | +$4,906 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-06-18 | A | A | 37,736 | $1.20 | 334,276 | D | — | — | |
| 2 | Derivative | Warrants | 2025-06-18 | A | A | 37,736 | $0.13 | 37,736 | D | $1.20 · 2025-06-18 to 2030-06-18 | 37,736 Common Shares |